Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment With Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B Virus (B-Well 1)
This study tested bepirovirsen, a medicine the FDA approved in October 2026 as Hibsago, to see how well it helps control chronic hepatitis B, a long-term liver infection. Researchers compared it with a placebo, both given on top of people's usual antiviral pills, to see whether it could keep the virus under control even after all hepatitis B treatment was stopped.
This study has been completed and is no longer enrolling. It enrolled adults with chronic hepatitis B who had taken the same antiviral pills (a nucleoside or nucleotide analogue) for at least 6 months, with the virus well controlled and a hepatitis B surface antigen (HBsAg) level above 100 and up to 3,000 IU/mL. People with cirrhosis, other serious liver diseases, or infections such as HIV, hepatitis C or hepatitis D could not take part.
Participants will go through several stages over about two years, which include taking the study drug or a placebo for 24 weeks, continuing standard care, and potentially stopping your regular antiviral pills to see how long the benefits last. You will have regular check-ups and monitoring throughout the process.
The study took place at 177 sites in 26 countries, including 12 in the United States (for example Los Angeles, Palo Alto, Miami, Detroit and Baltimore) and 8 in Canada (Toronto, Montreal, Ottawa, Vancouver, Victoria, Québec City and Saint-Jérôme), with the rest in Asia, Europe and Latin America. It has been completed and is no longer enrolling. Based on results from this study and a companion study (B-Well 2), the FDA approved bepirovirsen (Hibsago) on October 20, 2026 for certain adults with chronic hepatitis B without cirrhosis, given together with their usual antiviral treatment.
- 1Tested bepirovirsen, now FDA-approved as Hibsago, for chronic hepatitis B.
- 2Lasts up to approximately 104 weeks across multiple treatment and follow-up stages.
- 3Requires participants to already be on a stable routine of oral hepatitis B treatment.
Related videos
2Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.